Friday, 22 October 2010
AstraZeneca announced today that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the marketing authorisation application for FLUENZ Influenza Vaccine (Live attenuated, nasal), its nasally administered live attenuated influenza vaccine (LAIV) for prevention of seasonal influenza. The CHMP issued its opinion for marketing this product in Europe for children 24 months to less than 18 years of age.
The Committee’s positive opinion is now referred for a final decision by the European Commission (EC). The EC, which makes the decision whether to approve a new drug candidate for use in the European Union, typically decides within a few months of the CHMP issuing its opinion.
“Influenza creates a significant medical and economic burden on
Europe and throughout the world, and we are hopeful that the future
availability and product characteristics of this novel nasal spray
influenza vaccine will reduce the spread of influenza around the globe,”
said Alex Zukiwski, M.D., MedImmune’s executive vice president and
chief medical officer.
The positive opinion was reached after the CHMP reviewed data from 73
global clinical studies and US post-marketing studies of more than
141,000 subjects conducted in 38 countries. Study objectives have
included clinical safety and tolerability, clinical efficacy and
effectiveness, and immunogenicity.
NOTES TO EDITORS
About LAIV
Each dose of Fluenz is formulated to contain three live attenuated influenza virus strains, which are weakened so as to not cause illness. The vaccine strains are selected annually by the World Health Organization (WHO) based on anticipated circulating influenza strains for the upcoming season.
The vaccine is administered by spraying into the nose where it induces protective immunity. In several clinical studies it has demonstrated superior efficacy in children 24 months to less than 18 years of age compared to traditional inactivated influenza vaccines that are injected. The most common adverse events for LAIV are nasal congestion/rhinorrea, decreased appetite, headache, malaise and fever. The live influenza virus strains used in LAIV are cold-adapted, temperature sensitive and attenuated.
In the US, Fluenz is marketed by MedImmune under the trade name FluMist (Influenza Vaccine Live, Intranasal). FluMist was approved by the US Food and Drug Administration in 2003. The seasonal vaccine is currently approved in a further six countries including Canada.
About Influenza
Influenza is the most common vaccine-preventable disease in the developed world. According to WHO estimates, seasonal influenza results in three to five million cases of severe illness and up to half a million deaths globally each year, primarily among the elderly. Rates of infection are highest among children, with school-aged children significantly contributing to spread of disease to their families, communities and high-risk individuals.
Studies in several European countries have demonstrated that hospitalisation rates associated with influenza are highest in young children including those without underlying medical problems (Weigl et al, 2002; Pitman et al, 2007; Gasparini et al, 2007; Lenglet et al, 2007; Jansen et al, 2007). Based on these accumulated data, many experts include young children among those at high risk for severe influenza disease and influenza-related complications (Heikkinen et al, 2006).
Influenza also has socioeconomic consequences related to both direct and indirect health care costs, including hospitalisations, work absence and loss of work productivity when either a caregiver or child is sick with influenza.
To date, seven EU countries (Finland, Austria, Estonia, Latvia, the state of Saxony in Germany, Slovakia and Slovenia) recommend routinely vaccinating young children against influenza with varying age limits. EU and Member State policymakers continue to evaluate data on the impact of influenza in children to best inform the potential expansion of recommendations.
About MedImmune
MedImmune, the worldwide biologics unit for AstraZeneca PLC, has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune’s website at www.medimmune.com.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Neil McCrae +44 20 7604 8236 (24 hours)
Sarah Lindgreen +44 20 7604 8033 (24 hours)
Abigail Baron +44 20 7604 8034 (24 hours)
Investor Enquiries UK
Jonathan Hunt +44 20 7604 8122 mob: +44 7775 704032
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Clive Morris +44 20 7604 8124 mob: +44 7710 031012
Investor Enquiries US
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043